{"eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":4,"description":"Subjects will receive Pasireotide LAR monthly. Safety labs and Pituitary MRI will be performed.\n\nPasireotide LAR: Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use.\n\nThe starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained.","id":"EG000","otherNumAffected":0,"otherNumAtRisk":4,"seriousNumAffected":0,"seriousNumAtRisk":4,"title":"Pasireotide LAR Therapy"}],"frequencyThreshold":"5","timeFrame":"Up to 12 months"}